跳至主要内容
临床试验/CTRI/2021/04/032892
CTRI/2021/04/032892
尚未招募
2 期

A randomized controlled trial comparing the combination of oral mycophenolate mofetil and topical tacrolimus with topical tacrolimus monotherapy in acquired dermal macular hyperpigmentation

PGIMER0 个研究点目标入组 0 人待定

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
Health Condition 1: L819- Disorder of pigmentation, unspecified
发起方
PGIMER
状态
尚未招募
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Interventional

研究者

发起方
PGIMER

入排标准

入选标准

  • Patients with a diagnosis of ADMH as follows. 21
  • 1\. Clinical â?? Hyperpigmented, non\-scaly, macules and patches, either discrete or coalescing to form diffuse, blotchy, reticular or follicular patterns (must involve face and/or neck, may involve other body parts concomitantly)
  • 2\. Histopathological â?? An ongoing interface dermatitis with prominent melanin incontinence
  • 3\. Dermatoscopy â?? Presence of dots and globules.
  • 4\. An absent clinically apparent inflammatory phase prior to the appearance of the hyperpigmented patches.
  • Age \>18 years.
  • Consenting for inclusion in the study

排除标准

  • Age \< 18 years.
  • Patients with gastric and/or hepatic abnormalities.
  • Patients with known hemotological disease
  • Pateints with renal disease.
  • Known hypersensitivity to drug.
  • Clinically cured/ persistent malignancy
  • Active infection or immunodeficiency.
  • Pregnant or lactating women.

结局指标

主要结局

未指定

相似试验